JOHN F MURPHY
Broker in Lexington, MA
License number
Massachusetts 9084226
Issued Date
Nov 23, 2005
Expiration Date
Jun 6, 2008
Type
Salesperson
Address
Address
Lexington, MA 02420
Professional information
Enzymatically Active Toxin Coupled To A Cell-Specific Ligand
US Patent:
5080898, Jan 14, 1992
Filed:
Feb 21, 1989
Appl. No.:
7/313599
Inventors:
John R. Murphy - Lexington MA
Assignee:
The University Hospital - Boston MA
International Classification:
A61K 3748, A61K 3754, C12N 1500, C12N 1100
US Classification:
424 941
Abstract:
A cell-specific toxin molecule is prepared containing an enzymatically active toxin moiety coupled to a cell-specific binding ligand. The toxin moiety may be a diphtheria toxin, and has a non-naturally occurring cysteine residue encoded by a DNA sequence including a non-naturally occurring cysteine codon. The ligand may be a peptide hormone, proteinaceous growth factor, antibody of steroid hormone, and is derivatized with a sulfhydryl group reactive with the cysteine residue of the toxin moiety to couple the ligand to the toxin moiety via a disulfide bond. Derivatization of the ligand may be by providing the ligand with a non-naturally occurrring cysteine residue encoded by a DNA sequence including a non-naturally occurring cysteine codon. The toxin moiety exhibits cytotoxic activity but fails to exhibit generalized eukaryotic cell binding, and may be used to treat medical disorders.
Hybrid Protein
US Patent:
4675382, Jun 23, 1987
Filed:
Nov 6, 1985
Appl. No.:
6/795940
Inventors:
John R. Murphy - Lexington MA
Assignee:
President and Fellows of Harvard College - Cambridge MA
International Classification:
C07K 710, C07K 1300
US Classification:
530350
Abstract:
A hybrid protein including protein fragments joined together by peptide bonds, the hybrid protein including, in sequential order, beginning at the amino terminal end of the hybrid protein,
(a) the enzymatically active Fragment A of diphtheria
(b) a fragment including the cleavage domain 1. sub. 1 adjacent the Fragment A of diphtheria toxin,
(c) a fragment including at least a portion of the hydrophobic domain of Fragment B of diphtheria toxin and not including the generalized eukaryotic binding site of the Fragment B, and
(d) a fragment including a portion of a cell-specific polypeptide ligand, the portion including at least a portion of the binding domain of the polypeptide ligand, the portion of the binding domain being effective to cause the hybrid protein to bind selectively to a predetermined class of cells to be attacked by the enzymatically active Fragment A.